If you have heard that nicotine pouches are "tobacco-free" and wondered whether that means they cannot cause oral cancer, the honest answer from two new dental papers is: nobody knows yet — and that is not the same as a clean bill of health.

A peer-reviewed review published in Frontiers in Oral Health in February 2026, co-authored by University of Catania harm-reduction researcher Prof. Riccardo Polosa, lays out what is established, what is plausible, and what is simply missing. A separate update for the dental team in BDJ Team (Nature portfolio), published in April 2026 by clinicians at King’s College London and NHS England, adds what dentists are actually seeing in patients’ mouths right now.

Read together, they are a useful corrective to two opposite claims — that pouches are proven safe, and that they are just another form of smokeless tobacco cancer risk. Neither holds up.

What the review actually found

The starting point of the Frontiers paper is not controversial: tobacco smoking remains the most consistent and preventable risk factor for oral cancer worldwide. Cigarettes deliver more than 7,000 chemicals, at least 69 of them known carcinogens — polycyclic aromatic hydrocarbons, volatile aldehydes, and tobacco-specific nitrosamines. These combustion-derived toxins drive the DNA damage, inflammation and microbiome changes that turn oral cells malignant. Oral cancer is already the thirteenth most common cancer globally, and head and neck cancers are projected to rise nearly 30 percent by 2030.

The same review is blunt about how powerful smoking is as a risk factor: a recent meta-analysis it cites found that heavy drinking combined with heavy smoking increases oral cancer risk more than thirtyfold (relative risk 36.42). The worst oral cancer burdens sit in South and Southeast Asia, where unregulated, high-nitrosamine smokeless tobacco and areca nut use are deeply embedded.

This is the context nicotine pouches enter. Pouches are tobacco-leaf-free and, crucially, non-combustible. Toxicological analyses reviewed in the paper consistently show substantially lower levels of harmful constituents than cigarettes and traditional high-nitrosamine smokeless tobacco. Short-term human studies report improvements in gingival inflammation and reductions in pre-existing snus-associated mucosal lesions among people who switch.

The Swedish experience is offered as a signal, not proof: where snus largely replaced smoking, researchers observed lower tobacco-attributable mortality and no detectable increase in oral cancer risk at the population level. Pouches differ from snus in composition and regulation, but share the one feature that matters for this question — the absence of combustion.

What is still unknown

Here is where the review stops short. Oral cancer develops over long latency periods. Nicotine pouches have been on the market for less than a decade, so they cannot yet be judged by the epidemiological standards applied to cigarettes. The human studies that exist are few, small and heterogeneous. There is no long-term prospective evidence on pouches and oral carcinogenesis — full stop.

The authors are also candid about a credibility problem: much of the available toxicological evidence comes from industry-funded studies, which is why they call for independent toxicological assessment, standardized product testing, and surveillance of dual use and youth uptake.

"Smoking remains the primary cause of oral cancer worldwide. If we remove combustion, we remove the main source of carcinogenic exposure — but we must evaluate new products with scientific rigor, long-term data, and transparent surveillance," Prof. Polosa said. "Harm reduction is not about declaring products safe; it is about understanding relative risk."

The paper explicitly does not present pouches as risk-free. It situates them on a risk continuum: for adults who would otherwise smoke, or who use high-risk unregulated smokeless tobacco, removing combustion may substantially cut carcinogen exposure — balanced against regulatory oversight and honest communication of what is and is not known.

What dentists are seeing in mouths now

The BDJ Team update, written for working dental clinicians, grounds the same uncertainty in everyday practice. Nicotine pouches reached the UK market in 2019 and, until the Tobacco and Vapes Act takes effect, are regulated only under general product safety law — meaning no age restriction. More than half a million people in Great Britain now use them, with the sharpest growth among 16- to 24-year-olds, especially young men; around 3 percent of UK adults use pouches and a further 10 percent have tried them.

On general health, the dental-team update is matter-of-fact: nicotine is addictive and raises heart rate and blood pressure, and some pouch products have been found to contain harmful chemicals including formaldehyde, chromium and tobacco-specific nitrosamines. Long-term health effects are unknown. The authors nonetheless judge pouches likely to be a "substantially lower-risk product" than smoking.

The oral picture is more textured. Effects are unknown in the long term but probably resemble other orally-administered nicotine products. Dentists are told to watch for:

• Localized gum recession at the placement site.
• Mucosal changes where the pouch sits — ranging from slight wrinkling to white lesions — seemingly tied to how many pouches a day someone uses and for how long.
• Dry mouth, soreness, gingival blisters and a "strange jaw sensation" reported by some users.

The update is firm on one thing people often assume: there is currently no evidence that pouches work as a smoking-cessation aid, and because most users also smoke or vape, the dental team should follow standard tobacco-cessation advice rather than treat pouches as a proven quitting tool.

What this means for people who use pouches

The takeaway is not a verdict but a frame. On the question of oral cancer specifically, the established science says combustion is the danger, and pouches remove it — which is a real difference, not a marketing line. The missing science is whether that difference holds up over the decades-long horizon on which oral cancer develops, and whether other constituents in some products carry their own risks.

Until long-term data arrives, the reasonable positions are the ones the two papers occupy: pouches are not cigarettes, but they are not exonerated either. People who switch from smoking may reduce carcinogen exposure; people who add pouches on top of smoking get no such reassurance. And anyone noticing persistent mouth changes — recession, white patches, lesions that do not resolve — should have a dentist look, regardless of what is in the pouch.

---

Compare nicotine pouch brands and prices at PouchFinder.

SOURCES:

• La Rosa GRM, Samaranayake LP, Zaura E, Chapple I, Polosa R. "Nicotine pouches, oral cancer and tobacco harm reduction: current evidence and research priorities." Frontiers in Oral Health, 9 Feb 2026; 7:1761734. DOI: 10.3389/froh.2026.1761734. Open access: PMC12926464 | Frontiers
• Niven V, H. John J. "Oral nicotine pouches and oral health – an update for the dental team." BDJ Team 13, 152–153, 17 April 2026. DOI: 10.1038/s41407-026-3283-0. Nature BDJ Team
• CoEHAR (University of Catania). "Nicotine pouches and oral cancer: what we know — and what we still need to understand." 11 Feb 2026. coehar.org